Menu
Search
|

Menu

Close
X

Regenxbio Inc RGNX.OQ (NASDAQ Stock Exchange Global Select Market)

62.40 USD
-- (--)
As of Oct 18
chart
Previous Close 62.40
Open --
Volume --
3m Avg Volume 187,592
Today’s High --
Today’s Low --
52 Week High 85.05
52 Week Low 23.25
Shares Outstanding (mil) 30.89
Market Capitalization (mil) 1,039.60
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
172
FY17
10
FY16
5
FY15
8
EPS (USD)
FY18
3.342
FY17
-2.479
FY16
-2.383
FY15
-0.961
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.69
Price to Sales (TTM)
vs sector
117.63
5.82
Price to Book (MRQ)
vs sector
4.90
4.89
Price to Cash Flow (TTM)
vs sector
--
22.95
Total Debt to Equity (MRQ)
vs sector
0.00
17.15
LT Debt to Equity (MRQ)
vs sector
0.00
12.73
Return on Investment (TTM)
vs sector
-36.22
14.30
Return on Equity (TTM)
vs sector
-36.40
16.03

EXECUTIVE LEADERSHIP

Donald Hayden
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Kenneth Mills
President, Chief Executive Officer, Executive Director, Since 2009
Salary: $530,450.00
Bonus: --
Vittal Vasista
Chief Financial Officer, Since 2017
Salary: $365,400.00
Bonus: --
Patrick Christmas
Senior Vice President, General Counsel, Since 2016
Salary: --
Bonus: --
Ram Palanki
Senior Vice President - Commercial Strategy and Operations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9600 Blackwell Rd Ste 210
ROCKVILLE   MD   20850-3655

Phone: +1240.5528181

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

SPONSORED STORIES